Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation
JCO Precision Oncology · 2025-04 · (9)
DOI: 10.1200/po-24-00631 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025-04. Verfasst von Emanuel Krebs und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Control Research, BC Cancer Research Institute, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Melanoma, Cost-Benefit Analysis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Targeted therapy and immunotherapy promise improved survival in patients with advanced melanoma, yet the effectiveness and cost-effectiveness of multigene panel sequencing compared with single-gene BRAF testing to guide therapeutic decisions is unknown. METHODS Our population-based quasi-experimental retrospective target trial emulation used comprehensive patient-level data for 364 British Columbia, Canada, adults with an advanced melanoma diagnosis receiving multigene panel sequencing or single-gene BRAF testing between September 1, 2016, and December 31, 2018. We 1:1 matched multigene panel patients to controls using genetic algorithm–based matching. Outcomes included 3-year overall survival (OS) and health care costs (2021 Canadian dollars [CAD]) with incremental net monetary benefit for life-years gained (LYG). Outcomes were analyzed using inverse probability of censoring weighted linear regression for the intention-to-treat (ITT) effect. The per-protocol (PP) effect estimation also included stabilized inverse probability of treatment weights. We then used Weibull regression and Kaplan-Meier survival analysis. RESULTS We matched 147 multigene panel patients to controls, achieving balance for all covariates. After matching, ITT incremental costs were $19,447 CAD (95% CI, -$19,045 to $50,683) and incremental LYG were 0.22 (95% CI, –0.05 to 0.49). We found uncertainty in differences on OS using Kaplan-Meier ( P = .11) and Weibull regression (hazard ratio [HR], 0.73 [95% CI, 0.51 to 1.03]) in the ITT. PP incremental costs were $25,457 CAD (95% CI, –$5,856 to $59,490) and incremental LYG were 0.39 (95% CI, 0.02 to 0.85), with corresponding differences in OS using Kaplan-Meier ( P = .06) and Weibull regression (HR, 0.62 [95% CI, 0.40 to 0.97]). The probability of multigene panels being cost-effective at $100,000/LYG CAD was 53% for ITT and 74% for PP. CONCLUSION The cost-effectiveness of multigene panels was evenly poised at higher thresholds, even when accounting for treatment initiation. Health systems reimbursing multigene panels and expensive therapies may be confronted with a value tradeoff, in which there may be improved survival albeit with a modest change in cost-effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Cancer Control Research, BC Cancer Research Institute, Vancouver, BC, Canada.
- Faculty of Health Sciences, Simon Fraser University, Vancouver, BC.
- Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.
- Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
- Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
- Cancer Genetics & Genomics Laboratory, BC Cancer, Vancouver, BC, Canada.
ORCID-Profile: Emanuel Krebs, Deirdre Weymann, Cheryl Ho, Ian Bosdet, Aly Karsan, Timothy P Hanna, Samantha Pollard, Dean A Regier
Zitieren
APA
Krebs, E., Weymann, D., Ho, C., Weppler, A., Bosdet, I., Karsan, A., Hanna, T. P., Pollard, S., & Regier, D. A. (2025). Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation. JCO Precision Oncology. https://doi.org/10.1200/po-24-00631
Vancouver
Krebs E, Weymann D, Ho C, Weppler A, Bosdet I, Karsan A, et al. Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation. JCO Precision Oncology. 2025. doi:10.1200/po-24-00631
BibTeX
@article{Krebs2025,
author = {Krebs, Emanuel and Weymann, Deirdre and Ho, Cheryl and Weppler, Alison and Bosdet, Ian and Karsan, Aly and Hanna, Timothy P and Pollard, Samantha and Regier, Dean A},
title = {Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation},
journal = {JCO Precision Oncology},
year = {2025},
number = {9},
doi = {10.1200/po-24-00631}
}
EUVIMED